Copyright
©The Author(s) 2024.
World J Hepatol. Feb 27, 2024; 16(2): 140-145
Published online Feb 27, 2024. doi: 10.4254/wjh.v16.i2.140
Published online Feb 27, 2024. doi: 10.4254/wjh.v16.i2.140
Table 3 Interleukin-mediated therapies in liver disease
Clinical trials | Phase | Liver disease | Interleukin therapy |
NCT00565539 | 1 | Chronic hepatitis C virus (HCV) infection | PEGylated recombinant interleukin 29 (PEG-rIL-29) or in combination with daily oral ribavirin (an antiviral drug) |
NCT03882307 | 1 | Hepatitis C virus (HCV) infection | Test the association of serum levels of IL-6 and TGF-β in response to antiviral therapy (sofosbuvir and daclatasvir) for chronic hepatitis C patients |
NCT02431312 | 1 | Chronic hepatitis B | Evaluate the safety, tolerability, and immunogenicity of dose combinations of INO-1800 (DNA plasmids encoding hepatitis B surface antigen and hepatitis B core antigen) and INO-9112 (DNA plasmid encoding human interleukin 12) delivered by electroporation |
NCT02655510 | 1/2 | Alcoholic hepatitis | To test the efficacy of F-652, a recombinant fusion protein containing human IL-22 and human immunoglobulin G2 (IgG2)-Fc produced in CHO cells in serum-free culture |
NCT03775109 | 2 | Alcoholic hepatitis | To evaluate the potential benefits of the IL-1β antibody Canakinumab in the treatment of alcoholic hepatitis |
NCT01988506 | 2 | Autoimmune hepatitis, and other autoimmune and auto-inflammatory diseases | Low-dose IL-2 to induce regulatory T cells |
NCT00196586 | 2 | Chronic hepatitis C | Evaluate the efficacy and safety of the addition of IL-2 to pegylated interferon α-2a and ribavirin in patients with HCV/HIV coinfection |
NCT01697501 | 3 | Chronic hepatitis B | Evaluating the IL-28B polymorphism in patients with HBeAg-negative chronic hepatitis B treated with pegylated interferon α-2a |
NCT03090035 | 3 | Chronic hepatitis C | Test IL-28B (rs12979860) genotypes in patients with chronic hepatitis C infection treated with pegylated interferon α2 plus ribavirin |
NCT02360592 | 4 | Chronic hepatitis B | Evaluate the efficacy and safety of interferon α-2b therapy plus IL-2 and hepatitis B therapeutic vaccine compared to interferon α-2b alone |
NCT03734783 | Observational | Chronic hepatitis B | Investigate the levels of IL-35-secreting B regulatory cells in peripheral blood cells in patients with chronic hepatitis B and their functions on Th1 and Th2 cell levels |
- Citation: Yang M, Zhang CY. Interleukins in liver disease treatment. World J Hepatol 2024; 16(2): 140-145
- URL: https://www.wjgnet.com/1948-5182/full/v16/i2/140.htm
- DOI: https://dx.doi.org/10.4254/wjh.v16.i2.140